CG Oncology said on Monday that its experimental therapy cretostimogene cut the relative risk of bladder cancer recurrence by 68 percent compared with standard surveillance after surgery, meeting the main objective of a Phase 3 trial in people with intermediate-risk, high-grade non-muscle invasive bladder cancer. The result, after 17 months of follow-up, far surpassed the 30 to 40 percent risk reduction that management and investors had hoped for.
Safety was clean: investigators observed no drug-related adverse events rated severe or worse, and no patient stopped treatment because of side effects. CG Oncology shares climbed 12 percent on the results, pushing the company’s market value close to $8 billion. The company raised $380 million in its 2024 initial public offering.
Cretostimogene is an oncolytic virus immunotherapy, designed to infect and kill cancer cells while alerting the immune system. The standard of care in this setting is BCG immunotherapy after tumor resection, but many patients relapse, and some ultimately face removal of the bladder. This is the drug’s second Phase 3 success in a second setting: CG Oncology is already preparing an approval filing for patients who have not responded to BCG, expected to be completed early next year, and Monday’s results will support a further application next year in a setting that has no approved therapeutic option.
Analysts were emphatic but flagged the missing detail. TD Cowen’s Tyler Van Buren called the risk reduction exceptional and said cretostimogene is likely to be the only agent available in both settings. RBC Capital Markets analyst Leonid Timashev, who estimates peak United States sales of up to $3.2 billion by 2035, cautioned that the full dataset, to be presented at a medical meeting next month, will be critical to judging exactly how the drug performed.